anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The hepatic and renal tolerability of long-term naproxen administration was studied in two double-blind clinical trials involving 586 patients. Of the patients studied, 98 patients were age 65 and older and 10 of the 98 patients were age 75 and older. Naproxen was administered at doses of 375 mg twice daily or 750 mg twice daily for up to 6 months. Transient abnormalities of laboratory tests assessing hepatic and renal function were noted in some patients, although there were no differences noted in the occurrence of abnormal values among different age groups.

Elderly patients, compared to younger patients, are at greater risk for NSAID-associated serious cardiovascular, gastrointestinal, and/or renal adverse reactions. If the anticipated benefit for the elderly patient outweighs these potential risks, start dosing at the low end of the dosing range, and monitor patients for adverse effects [ see Warnings and Precautions (5.1, 5.2, 5.3, 5.6, 5.14)]. 

Studies indicate that although total plasma concentration of naproxen is unchanged, the unbound plasma fraction of naproxen is increased in the elderly. The clinical significance of this finding is unclear, although it is possible that the increase in free naproxen concentration could be associated with an increase in the rate of adverse events per a given dosage in some elderly patients. Caution is advised when high doses are required and some adjustment of dosage may be required in elderly patients. As with other drugs used in the elderly, it is prudent to use the lowest effective dose.

Experience indicates that geriatric patients may be particularly sensitive to certain adverse effects of nonsteroidal anti-inflammatory drugs. Elderly or debilitated patients seem to tolerate peptic ulceration or bleeding less well when these events do occur. Most spontaneous reports of fatal GI events are in the geriatric population [ see Warnings and Precautions (5.2)]. 

Naproxen is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function [ see Clinical Pharmacology (12.3)]. Geriatric patients may be at a greater risk for the development of a form of renal toxicity precipitated by reduced prostaglandin formation during administration of nonsteroidal anti-inflammatory drugs [ see Warnings and Precautions (5.6)].
Hydroxylapatite (CustomBone) implant Hydroxylapatite implants are used since about 3 years in Germany. As this material is very similar to human bone structure an improved osteointegration has been observed.
OBJECTIVES: I. Determine the maximum tolerated dose of flavopiridol when administered in combination with paclitaxel and cisplatin in patients with refractory adult solid tumors. II. Investigate the clinical pharmacokinetics of intravenous flavopiridol when administered in combination with paclitaxel in these patients. III. Obtain preliminary data on the therapeutic activity of flavopiridol when administered in combination with paclitaxel in these patients. IV. Evaluate surrogate markers of activity such as inhibition of PKC or CDK1 in these patients.

OUTLINE: This is an open label, dose escalation study. Patients receive paclitaxel IV over 3 hours on day 1. On day 2, patients receive cisplatin IV over 20 minutes followed by a 24 hour infusion of flavopiridol. Courses are repeated every 21 days in the absence of disease progression or unacceptable toxicity. Sequential dose escalation of flavopiridol is followed by sequential dose escalation of cisplatin. Dose escalation in cohorts of 3-6 patients each continues until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose limiting toxicity. Patients are followed every 6 weeks.

PROJECTED ACCRUAL: Approximately 46-73 patients will be accrued for this study within 6 more months.
Composition for skin care and for assisting skin renewal comprises: (a) a soln. of hyaluronic acid and a protein fraction in water or dilute (< 10 vol.%) alcohol, where the soln. can be used as a spray, or (b) a soln. of an alkali(ne earth) metal hyaluronate and physiologically active peptide in water. The peptides are of animal, microbial or pref. plant origin.  The compsn. of (a) and (b) preferably contains 0.05-2.5 wt.% Na hyaluronate, 0.025-2.5 wt.% of a protein fraction or physiologically active peptide of plant origin, opt. up to 2% of heparin or other physiologically acceptable mucopolysaccharide, and opt. plant oils, plant extracts, essential oils and/or stabilisers such as emulsifier, thickeners or preservatives.
For use in radiography, a heavy metal salt opaque to X-rays is obtained in a state of fine division by reacting upon a compound of the metal with a soluble non-poisonous salt in excess in the presence of gelatine, this salt precipitating the desired metal salt but not precipitating the gelatine.  Excess of the soluble salt is removed by washing.  In the example, a solution of barium chloride is slowly added to a solution of ammonium sulphate in the presence of gelatine. The mixture is stirred for about fifteen minutes and the temperature maintained at about 110 DEG  F.  The ammonium sulphate is always in excess, but a small quantity of sulphuric acid may be added to the mixture as a safeguard.  When the emulsion is finished, additional gelatine is added to ensure setting and to smooth off the emulsion. The jelly when set is divided into shreds, washed, and quickly dried. The final product is in the form of blocks, flakes or powder.ALSO:A process for the production of a preparation to be taken internally by a patient before radiographic examination comprises an emulsification stage in which a heavy metal salt opaque to X-rays is emulsified with gelatine under determined conditions of agitation and stirring, the said metal salt being in an exceedingly fine state of division and becoming uniformly distributed throughout the emulsion.  The fine state of division is attained by reacting upon a compound of the metal with a soluble non-poisonous salt in excess in the presence of gelatine, this salt having a capacity for precipitating the desired metal salt and an incapacity for precipitating the gelatine.  Excess of the soluble salt is removed by washing and the resulting gelatinous mass containing the heavy metal salt constitutes a product adapted for administration with ordinary food.  In the example given, a solution of barium chloride is slowly added to a solution of ammonium sulphate in the presence of gelatine.  The mixture is stirred for about fifteen minutes and the temperature maintained at about 110 DEG  F.  The ammonium sulphate is always in excess but a small quantity of sulphuric acid may be added to the mixture as a safeguard.  When the emulsion is finished, additional gelatine is added to ensure setting and to smooth off the emulsion.  The jelly when set is divided into shreds, washed, and quickly dried.  The final product is in the form of blocks, flakes or powder.  The product may be administered to a patient in the form of a jelly, blanc mange &c.
In Part 2 of this combined Phase 1/2 study, 374 adults aged 18-75 years will be randomized (1:1:1) to placebo, or COVIVAC 3 µg being evaluated in Phase 1 or the intermediate dose of COVIVAC 6 µg being selected after consideration of phase 1 results. At least one-third of the subjects in Phase 2 will be aged ≥60 years to ensure that adequate safety and immune data will be available from older and elderly adults to inform the selection of the COVIVAC formulation to advance to Phase 3 studies. The Phase 2 cohort will follow the same visit schedule, and undergo the same procedures and assessments, as in Phase 1. In addition, as exploratory objectives, the anti-NDV HN IgG response will be assessed at V1, V3, V5, and V7 in all subjects, and 36 subjects (equally distributed between the two age strata) will be randomly selected in a 1:1:1 ratio to provide additional blood at V1, V5 and V7 to be used to isolate peripheral blood mononuclear cells (PBMCs) for assessment of T-cell-mediated immunity (CMI).

An interim analysis of Phase 2 data will be conducted after the last subject of the Phase 2 cohort completes V6 (D57) as the basis for selecting the optimal formulation of COVIVAC to advance to Phase 3 studies. As was the case for the Phase 1 interim analysis at the same timepoint, the data generated will include unblinded post-dose 1 and dose 2 safety results for review by the DSMB, and immunogenicity results aggregated by treatment group for review by the Sponsor. The DSMB will consider all accumulated safety data from both phases of the study prior to making any recommendation to the Sponsor that it not advance a formulation based on safety concerns. The Sponsor will ultimately select the formulation to advance to Phase 3 that, in addition to having been judged by the DSMB to have an adequate safety and tolerability profile, is optimal based on relative functional immunogenicity and other programmatic considerations such as those noted above.
Pregnancy Category C:

There are no adequate and well controlled studies of dexmethylphenidate hydrochloride in pregnant women. Dexmethylphenidate did not cause major malformations in rats or rabbits; however, it did cause delayed skeletal ossification and decreased postweaning weight gain in rats. Dexmethylphenidate hydrochloride extended-release capsules should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

In studies conducted in rats and rabbits, dexmethylphenidate was administered orally at doses of up to 20 and 100 mg/kg/day, respectively, during the period of organogenesis. No evidence of teratogenic activity was found in either the rat or rabbit study; however, delayed fetal skeletal ossification was observed at the highest dose level in rats. When dexmethylphenidate was administered to rats throughout pregnancy and lactation at doses of up to 20 mg/kg/day, postweaning body weight gain was decreased in male offspring at the highest dose, but no other effects on postnatal development were observed. At the highest doses tested, plasma levels (AUCs) of dexmethylphenidate in pregnant rats and rabbits were approximately 5 and 1 times, respectively, those in adults dosed with 20 mg/day.

Racemic methylphenidate has been shown to have teratogenic effects in rabbits when given in doses of 200 mg/kg/day throughout organogenesis.
The present invention relates to the field of vaccination, in particular, of vaccination against hepatitis C virus (HCV). The present invention provides a composition comprising at least parts of the HCV core protein, and HCV E1 and HCV E2 protein of a specific HCV strain, as well as VSV-G protein. The proteins may be assembled in rVSV-HCV particles. This has been identified to induce particularly advantageous broadly neutralizing antibodies. The invention further provides nucleic acids encoding said HCV proteins and VSV proteins but not encoding VSV-G protein. Vaccines comprising the particles, compositons or nucleic acids are disclosed as useful, in particular, for prophylactic vaccination against HCV. Methods of producing the rVSV-HCV particles or compositons of the invention and the produced particles and compositons are also subject-matter of the invention.
PROBLEM TO BE SOLVED: To obtain a cosmetic wherein development of heterogeneous phenomenon of the cosmetic is suppressed by including a perfluoro-treated powder and a powder having oil-absorbing ability. SOLUTION: This cosmetic is obtained by including (A) a perfluoro-treated powder, (B) a powder having oil absorption (pref. silica-coated mica or the like) and pref. furthermore (C) a powder having water absorpting ability (pref. a water-insoluble or sparingly soluble silicate or the like). It is preferable that the component A is a powder treated with a salt of a compound of formula I [(n) is 1-2; (m) is 1-3] and/or a powder treated with a compound of formula II (R1 to R3 are each an 1-4C alkyl). It is also preferable that the component B has an oil absorption of >=75 ml/100 g when linseed oil in oils and fats is substituted with glyceryl trioctanoate in the measurement of an oil absorption in accordance with JIS K 5101-1991. This cosmetic is pref. a makeup cosmetic for summer.
Subjects will receive a bolus intravenous (IV) infusion of 20 mcg/kg/min of milrinone lactate over 1 hour followed by a continuous IV infusion of 0.2 mcg/kg/min milrinone lactate over 24 hours. After completion of infusion, subjects will be monitored for an additional 24 hours.
Magnesium Sulfate in Water for Injection is a sterile, nonpyrogenic solution of magnesium sulfate heptahydrate in water for injection. May contain sulfuric acid and/or sodium hydroxide for pH adjustment. The pH is 4.5 (3.5 to 6.5). It is available in a 4% and 8% concentrations. See HOW SUPPLIED section for the content and characteristics of available dosage forms and sizes.

Magnesium Sulfate, USP heptahydrate is chemically designated MgSO4 • 7H2O, colorless crystals or white powder freely soluble in water.

Water for Injection, USP is chemically designated H2O.

VIAFLO container is a flexible plastic container fabricated from a multilayer sheeting composed of Polypropylene (PP), Polyamide (PA) and Polyethylene (PE). The amount of water that can permeate from the container into the overwrap is insufficient to affect the solution significantly. Solutions in contact with the flexible container can leach out certain of the container’s chemical components in very small amounts within the expiration period. The suitability of the container material has been confirmed by tests in animals according to USP biological tests for plastic containers. Exposure to temperatures above 25°C/77°F during transport and storage will lead to minor losses in moisture content. Higher temperatures lead to greater losses. It is unlikely that these minor losses will lead to clinically significant changes within the expiration period.
The product provides a cefixime orally disintegrating tablet. The cefixime orally disintegrating tablet contains cefixime, microcrystalline cellulose, low-substituted hydroxy propyl cellulose, crosslinking polyvinylpyrrolidone, mannitol, aspartame, magnesium stearate, etc., wherein each tablet contains 100mg of cefixime. The cefixime orally disintegrating tablet of the invention is convenient for taking, can be taken without water, is fast disintegrated in an oral cavity, and has no delay phenomenon in an esophagus. Greatly convenience is provided for children, the elderly, patients with mental diseases, and bedridden patients who are difficult to move. Characteristic of fast disintegration in the oral cavity makes a drug absorption area increase, and the cefixime orally disintegrating tablet has advantage of easy and rapid absorption, small irritation on an alimentary canal mucous membrane and high bioavailability. The cefixime orally disintegrating tablet is convenient for carrying and taking. Compared with a common solid oral preparation, the cefixime orally disintegrating tablet can be fast absorbed, provides greatly convenience for patients, greatly raises treatment compliance, and has a good clinic application prospect. The cefixime orally disintegrating tablet of the invention has a simple preparation method, is suitable for industrialization production, and has a great application value.
An eye paste with a healthcare function comprises an eye paste body stained with care essence liquid. The eye paste body is composed of a left eye paste body, a right eye paste body and a connecting paste belt which are made of same materials and are of an integrated structure. The shape of the eye paste body is matched with that of the eyes of a human body. The left eye paste body and the right eye paste body are provided with magnetic sheets corresponding to the cuanzhu points, the yuyao points, the sizhukong points, the taiyang points, the tongziliao points, the jingming points and the chengqi points of the eyes of the human body. A heating layer is arranged on the eye paste body provided with the magnetic sheets, and a protecting film is arranged on the upper end face of the heating layer in an adhering mode. The eye paste has the good care, beauty and healthcare effects on the eyes.
The present invention relates to a metadoxine chewable tablet and a preparation method thereof. The metadoxine chewable tablet is composed of metadoxine, a filling agent as a main medicine, corrigent, glidant, a flavoring agent and an adhesive. The metadoxine chewable tablet can be used for patients who have difficulty in swallowing common tablets, and the medicine elasticity is favorable. After put in a mouth for chewing, the metadoxine chewable tablet can dissolve in sputum. The metadoxine chewable tablet can be absorbed by a mucous membrane of a mouth cavity or an esophagus, and the biologic utilization degree is high. The metadoxine chewable tablet has the advantages of sweet taste, good mouth feelings, convenient administration and portability, and is prepared by a direct tablet pressing method. The penetrating odor is corrected, and the metadoxine chewable tablet has fragrance, and has the advantages of high stability, simple preparation technology and low cost.
PURPOSE: To provide a dye compsn. which does not damage the scalp and hair fibril but in effective and durable so that hair can be dyed with good resistance against washing. CONSTITUTION: This enzyme-based dye compsn. contains at least an enzyme which can act as a catalyst to produce colorant polymers and contains a matrix and a dye precursor such as a coloring agent. The compsn. is used in a buffer soln. to dye keratin fiber especially hair without irradiation of light. The pH of the compsn. is almost neutral and the enzyme has the optimum activity in 6.5 to 8 pH range. The enzyme does not require hydrogen peroxide for its activity. The enzyme is preferably laccase, especially Rhizoctonia platycora laccase of Rhus vernicifera laccase.
Osteoarthritis (OA) is a major contributor to disability and social costs in the elderly. As the population ages and becomes increasingly obese, the incidence of the disease is higher than in previous decades. In recent years, important progress has been made in the causes and pathogenesis of OA pain. Modern medical treatment modalities mainly include the specific situation of the patient and focus on the core treatment, including self-management and education, exercise, and related weight loss. As an important part of complementary and alternative medicine, TCM has remarkable curative effect, clinical safety, and diversity of treatment methods in the treatment of OA. Traditional Chinese Medicine treatment of OA has attracted worldwide attention. Therefore, this article will study the pathophysiological mechanism of OA based on modern medicine, and explore the treatment of OA by acupuncture combined with Chinese Medicine.
The intervention group will start with a Delfi tourniquet system cuff set on a limb occlusion pressure (LOP) of 60-100%. The intervention group will also use a neuromuscular electrical stimulation device at therapeutic level in addition to BFR.
INTRODUCTION: Diabetes is associated with dysregulated immune function and impaired cytokine release, while transient acute hyperglycaemia has been shown to enhance inflammatory cytokine release in preclinical studies. Although diabetes and acute hyperglycaemia are common among patients with community-acquired pneumonia (CAP), the impact of chronic, acute, and acute-on-chronic hyperglycaemia on the host response within this population remains poorly understood. This study investigated whether chronic, acute, and acute-on- chronic hyperglycaemia are associated with distinct mediators of inflammatory, endothelial, and angiogenic host response pathways in patients with CAP.
METHODS: In a cross-sectional study of 555 patients with CAP, HbA1c, admission plasma (p)-glucose, and the glycaemic gap (admission p-glucose minus HbA1c- derived average p-glucose) were employed as measures of chronic, acute, and acute-on-chronic hyperglycaemia, respectively. Linear regression was used to model the associations between the hyperglycaemia measures and 47 proteins involved in inflammation, endothelial activation, and angiogenesis measured at admission. The models were adjusted for age, sex, CAP severity, pathogen, immunosuppression, comorbidity, and body mass index. Adjustments for multiple testing were performed with a false discovery rate threshold of less than 0.05.
RESULTS: The analyses showed that HbA1c levels were positively associated with IL-8, IL-15, IL-17A/F, IL-1RA, sFlt-1, and VEGF-C. Admission plasma glucose was also positively associated with these proteins and GM-CSF. The glycaemic gap was positively associated with IL-8, IL-15, IL-17A/F, IL-2, and VEGF-C.
CONCLUSION: In conclusion, chronic, acute, and acute-on-chronic hyperglycaemia were positively associated with similar host response mediators. Furthermore, acute and acute-on-chronic hyperglycaemia had unique associations with the inflammatory pathways involving GM-CSF and IL-2, respectively.
INTRODUCTION: Visceral obesity is a risk factor for reflux esophagitis (RE). We investigated the risk of RE according to visceral adipose tissue (VAT) measured by deep neural network architecture using computed tomography (CT) and evaluated the longitudinal association between abdominal adipose tissue changes and the disease course of RE.
METHODS: Individuals receiving health checkups who underwent esophagogastroduodenoscopy (EGD) and abdominal CT at Seoul National University Healthcare System Gangnam Center between 2015 and 2016 were included. Visceral and subcutaneous adipose tissue areas and volumes were measured using a deep neural network architecture and CT. The association between the abdominal adipose tissue area and volume and the risk of RE was evaluated. Participants who underwent follow-up EGD and abdominal CT were selected; the effects of changes in abdominal adipose tissue area and volume on RE endoscopic grade were investigated using Cox proportional hazards regression.
RESULTS: We enrolled 6,570 patients who underwent EGD and abdominal CT on the same day. RE was associated with male sex, hypertension, diabetes, excessive alcohol intake, current smoking status, and levels of physical activity. The VAT area and volume increased the risk of RE dose-dependently. A decreasing VAT volume was significantly associated with improvement in RE endoscopic grade (hazard ratio: 3.22, 95% confidence interval: 1.82-5.71). Changes in subcutaneous adipose tissue volume and the disease course of RE were not significantly correlated.
DISCUSSION: Visceral obesity is strongly associated with RE. VAT volume reduction was prospectively associated with improvement in RE endoscopic grade dose-dependently. Visceral obesity is a potential target for RE treatment.